Fremanezumab, formerly known as TEV-48125, is a fully humanized immunoglobulin G2 monoclonal antibody that potently and selectively binds to calcitonin gene-related peptide (CGRP), thereby preventing its binding to receptors, indicated for the prevention of episodic or chronic migraine in adults.
Specifications
Catalog Number:
KB-1047
Antibodies Name:
Fremanezumab
Host Cell Line:
EXPI-CHO
Target:
CGRP
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA
Characterization
Application
References
1.Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999ÿ2008.
2.Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113ÿ2122.
